Health
Molnupiravir (MK-4482/EIDD-2801) Antiviral — Precision Vaccinations – PrecisionVaccinations
Molnupiravir (MK-4482/EIDD-2801) antiviral is indicated to mitigate SARS-CoV-2 infection and block transmission, hence preventing COVID-19 disease.
Molnupiravir (MK-4482/EIDD-2801) Antiviral Description
Molnupiravir (MK-4482/EIDD-2801) is an oral antiviral drug that was originally developed for the treatment of influenza. MK-4482/EIDD-2801 consists of the nucleoside analogue N4-hydroxycytidine (NHC). Molnupiravir has been evaluated against coronaviruses (CoVs) including SARS-1, MERS-CoV, and SARS-CoV-2.
The drug was originally developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE)….
-
General13 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News20 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business21 hours agoBell Potter names the best ASX shares to buy in October
-
General19 hours agoAustralia welcomes Gaza peace progress, hostage release